Synopsis
Synopsis
0
FDA Orange Book
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Acid, Hyaluronic
2. Amo Vitrax
3. Amvisc
4. Biolon
5. Etamucine
6. Healon
7. Hyaluronate Sodium
8. Hyaluronate, Sodium
9. Hyaluronic Acid
10. Hyvisc
11. Luronit
12. Vitrax, Amo
1. Hyaluronic Acid, Sodium Salt
2. Hyaluronic Acid Sodium
3. Kopuron
4. Healon
5. Hyalgan
6. Hyalurone Sodium
7. 6-[3-acetamido-2-[6-[3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic Acid
8. Sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic Acid
9. Equron (veterinary)
10. Synacid (veterinary)
11. Arthrease
12. Cystistat
13. Hyalart
14. Hyalein
15. Hyalovet
16. Hyladerm
17. Khionat
18. Monovisc
19. Nidelon
20. Orthovisc
21. Ostenil
22. Provisc
23. Sinovial
24. Supartz
25. Suvenyl
26. Hyasol
27. Hyladerm Khionat
28. Nrd101
29. Ha
30. Hyaluronsan Ha-lq
31. Bio Hyaluro 12
32. Euflexxa Injection
33. Euflexxa
34. Ccris 4127
35. Hyaluronate Sodium [usan:jan]
36. Sodium Hyaluronate Hmw
37. Unii-yse9ppt4th
38. Si-4402
39. Sl-1010
40. Synacid
41. Equron
42. Chlamyhyaluronic Acid Sodium Salt
43. Sl 1010
44. Hyalauronic Acid 99%
45. Yse9ppt4th
46. Gtpl4954
47. Sodium Hyaluronate (food Grade)
48. Sodium Hyaluronate (cosmetic Grade)
49. Akos015896610
50. Sodium Hyaluronate, Low Molecular Weight
51. Sodium Hyaluronate, High Molecular Weight
52. Q27078001
53. (3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-4-[(2s,3r,4s,6s)-6-carboxy-3,4,5-trihydroxy-tetrahydropyran-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-6-[(3r,4r,5s,6r)-3-acetamido-2,5-dih
54. Sodium (2s,3s,4r,5r,6r)-3-{[(2s,3r,4r,5s,6r)-4-{[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy}-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-{[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4,5-dihydroxyoxane-2-carboxylic Acid
Molecular Weight | 799.6 g/mol |
---|---|
Molecular Formula | C28H44N2NaO23+ |
Hydrogen Bond Donor Count | 14 |
Hydrogen Bond Acceptor Count | 23 |
Rotatable Bond Count | 12 |
Exact Mass | 799.22325494 g/mol |
Monoisotopic Mass | 799.22325494 g/mol |
Topological Polar Surface Area | 400 Ų |
Heavy Atom Count | 54 |
Formal Charge | 1 |
Complexity | 1300 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 20 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Adjuvants, Immunologic
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)
Viscosupplements
Viscoelastic solutions that are injected into JOINTS in order to alleviate symptoms of joint-related disorders such as OSTEOARTHRITIS. (See all compounds classified as Viscosupplements.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Hyaluronate Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Hyaluronate Sodium, including repackagers and relabelers. The FDA regulates Hyaluronate Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Hyaluronate Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Hyaluronate Sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Hyaluronate Sodium supplier is an individual or a company that provides Hyaluronate Sodium active pharmaceutical ingredient (API) or Hyaluronate Sodium finished formulations upon request. The Hyaluronate Sodium suppliers may include Hyaluronate Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Hyaluronate Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Hyaluronate Sodium DMF (Drug Master File) is a document detailing the whole manufacturing process of Hyaluronate Sodium active pharmaceutical ingredient (API) in detail. Different forms of Hyaluronate Sodium DMFs exist exist since differing nations have different regulations, such as Hyaluronate Sodium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Hyaluronate Sodium DMF submitted to regulatory agencies in the US is known as a USDMF. Hyaluronate Sodium USDMF includes data on Hyaluronate Sodium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Hyaluronate Sodium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Hyaluronate Sodium suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Hyaluronate Sodium Drug Master File in Japan (Hyaluronate Sodium JDMF) empowers Hyaluronate Sodium API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Hyaluronate Sodium JDMF during the approval evaluation for pharmaceutical products. At the time of Hyaluronate Sodium JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Hyaluronate Sodium suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Hyaluronate Sodium Drug Master File in Korea (Hyaluronate Sodium KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Hyaluronate Sodium. The MFDS reviews the Hyaluronate Sodium KDMF as part of the drug registration process and uses the information provided in the Hyaluronate Sodium KDMF to evaluate the safety and efficacy of the drug.
After submitting a Hyaluronate Sodium KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Hyaluronate Sodium API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Hyaluronate Sodium suppliers with KDMF on PharmaCompass.
A Hyaluronate Sodium CEP of the European Pharmacopoeia monograph is often referred to as a Hyaluronate Sodium Certificate of Suitability (COS). The purpose of a Hyaluronate Sodium CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Hyaluronate Sodium EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Hyaluronate Sodium to their clients by showing that a Hyaluronate Sodium CEP has been issued for it. The manufacturer submits a Hyaluronate Sodium CEP (COS) as part of the market authorization procedure, and it takes on the role of a Hyaluronate Sodium CEP holder for the record. Additionally, the data presented in the Hyaluronate Sodium CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Hyaluronate Sodium DMF.
A Hyaluronate Sodium CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Hyaluronate Sodium CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Hyaluronate Sodium suppliers with CEP (COS) on PharmaCompass.
A Hyaluronate Sodium written confirmation (Hyaluronate Sodium WC) is an official document issued by a regulatory agency to a Hyaluronate Sodium manufacturer, verifying that the manufacturing facility of a Hyaluronate Sodium active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Hyaluronate Sodium APIs or Hyaluronate Sodium finished pharmaceutical products to another nation, regulatory agencies frequently require a Hyaluronate Sodium WC (written confirmation) as part of the regulatory process.
click here to find a list of Hyaluronate Sodium suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Hyaluronate Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Hyaluronate Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Hyaluronate Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Hyaluronate Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Hyaluronate Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Hyaluronate Sodium suppliers with NDC on PharmaCompass.
Hyaluronate Sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Hyaluronate Sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Hyaluronate Sodium GMP manufacturer or Hyaluronate Sodium GMP API supplier for your needs.
A Hyaluronate Sodium CoA (Certificate of Analysis) is a formal document that attests to Hyaluronate Sodium's compliance with Hyaluronate Sodium specifications and serves as a tool for batch-level quality control.
Hyaluronate Sodium CoA mostly includes findings from lab analyses of a specific batch. For each Hyaluronate Sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Hyaluronate Sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Hyaluronate Sodium EP), Hyaluronate Sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Hyaluronate Sodium USP).
LOOKING FOR A SUPPLIER?